Buscar
Mostrando ítems 21-30 de 30
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
(Massachusetts Medical Society, 2021)
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
(Massachusetts Medical Society, 2021)
Long-acting antiretroviral therapy
Nanoformulations of cabotegravir prodrugs have been developed to prolong the pharmacokinetics of the
antiretroviral agent. They can be present in the plasma of mice and non-human primates for a year following
a single injection.
Sustained release of antiretroviral therapy from nanochannel delivery implant for HIV pre-exposure prophylaxis and treatment
(Instituto Tecnológico y de Estudios Superiores de Monterrey, 2021-04-08)
HIV-1 pre-exposure prophylaxis (PrEP) adherence and implementation challenges, including pill fatigue and limited medical access, have motivated research into long-acting (LA) strategies such as formulations or controlled ...
PrEP policy implementation gaps and opportunities in Latin America and the Caribbean: a scoping review.
(SAGE Publications, 2023)
BACKGROUND: Pre-exposure prophylaxis (PrEP) is an important tool for HIV prevention in Latin America and the Caribbean (LAC). Yet, little is known about the PrEP policies landscape in the region. Addressing this gap, this ...
Prevalência de mutações de resistência aos antirretrovirais em pacientes com falha virológica em uso do raltegravir em regimes de terapia de resgate
(Universidade Federal de São Paulo (UNIFESP), 2021)
The integrase enzyme is fundamental to the HIV virus replication process, being responsible for the integration of viral DNA into the host cell genome, andgenome and is therefore a potential target for rescue treatment ...